234 related articles for article (PubMed ID: 9875414)
1. 3-Hydroxyphthaloyl beta-lactoglobulin. IV Antiviral activity in the mouse model of genital herpesvirus infection.
Kokuba H; Aurelian L; Neurath AR
Antivir Chem Chemother; 1998 Jul; 9(4):353-7. PubMed ID: 9875414
[TBL] [Abstract][Full Text] [Related]
2. 3-Hydroxyphthaloyl beta-lactoglobulin. III. Antiviral activity against herpesviruses.
Neurath AR; Strick N; Li YY
Antivir Chem Chemother; 1998 Mar; 9(2):177-84. PubMed ID: 9875389
[TBL] [Abstract][Full Text] [Related]
3. Cellulose acetate phthalate (CAP): an 'inactive' pharmaceutical excipient with antiviral activity in the mouse model of genital herpesvirus infection.
Gyotoku T; Aurelian L; Neurath AR
Antivir Chem Chemother; 1999 Nov; 10(6):327-32. PubMed ID: 10628808
[TBL] [Abstract][Full Text] [Related]
4. A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2.
Parr MB; Kepple L; McDermott MR; Drew MD; Bozzola JJ; Parr EL
Lab Invest; 1994 Mar; 70(3):369-80. PubMed ID: 8145530
[TBL] [Abstract][Full Text] [Related]
5. Antiviral and immunological effects of tenofovir microbicide in vaginal herpes simplex virus 2 infection.
Vibholm L; Reinert LS; Søgaard OS; Paludan SR; Østergaard L; Tolstrup M; Melchjorsen J
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1404-11. PubMed ID: 22867119
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic effect of meliacine, an antiviral derived from Melia azedarach L., in mice genital herpetic infection.
Petrera E; Coto CE
Phytother Res; 2009 Dec; 23(12):1771-7. PubMed ID: 19441066
[TBL] [Abstract][Full Text] [Related]
7. Effect of resveratrol on herpes simplex virus vaginal infection in the mouse.
Docherty JJ; Fu MM; Hah JM; Sweet TJ; Faith SA; Booth T
Antiviral Res; 2005 Sep; 67(3):155-62. PubMed ID: 16125258
[TBL] [Abstract][Full Text] [Related]
8. Observations on recovery from and recurrence of HSV-2 infections in adult mice that were rescued from lethal vaginal infection by antiviral therapy.
Parr EL; Holliday EM; Collard MW; Parr MB
Arch Virol; 2005 Sep; 150(9):1885-902. PubMed ID: 15824886
[TBL] [Abstract][Full Text] [Related]
9. An update on short-course episodic and prevention therapies for herpes genitalis.
Corey L; Bodsworth N; Mindel A; Patel R; Schacker T; Stanberry L
Herpes; 2007 Jun; 14 Suppl 1():5A-11A. PubMed ID: 17877886
[TBL] [Abstract][Full Text] [Related]
10. An immunomodulating dipeptide, SCV-07, is a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2).
Rose WA; Tuthill C; Pyles RB
Int J Antimicrob Agents; 2008 Sep; 32(3):262-6. PubMed ID: 18619817
[TBL] [Abstract][Full Text] [Related]
11. NK and NKT cell-independent contribution of interleukin-15 to innate protection against mucosal viral infection.
Gill N; Rosenthal KL; Ashkar AA
J Virol; 2005 Apr; 79(7):4470-8. PubMed ID: 15767447
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of a natural carrageenan on genital herpes simplex virus infection in mice.
Carlucci MJ; Scolaro LA; Noseda MD; Cerezo AS; Damonte EB
Antiviral Res; 2004 Nov; 64(2):137-41. PubMed ID: 15498610
[TBL] [Abstract][Full Text] [Related]
13. Management of herpes simplex virus type 2 infection in HIV type 1-infected persons.
Strick LB; Wald A; Celum C
Clin Infect Dis; 2006 Aug; 43(3):347-56. PubMed ID: 16804851
[TBL] [Abstract][Full Text] [Related]
14. Estradiol regulates susceptibility following primary exposure to genital herpes simplex virus type 2, while progesterone induces inflammation.
Gillgrass AE; Fernandez SA; Rosenthal KL; Kaushic C
J Virol; 2005 Mar; 79(5):3107-16. PubMed ID: 15709030
[TBL] [Abstract][Full Text] [Related]
15. Chemical properties, mode of action, and in vivo anti-herpes activities of a lignin-carbohydrate complex from Prunella vulgaris.
Zhang Y; But PP; Ooi VE; Xu HX; Delaney GD; Lee SH; Lee SF
Antiviral Res; 2007 Sep; 75(3):242-9. PubMed ID: 17475343
[TBL] [Abstract][Full Text] [Related]
16. Effect of polyanionic compounds on intracutaneous and intravaginal herpesvirus infection in mice: impact on the search for vaginal microbicides with anti-HIV activity.
Neyts J; De Clercq E
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):8-12. PubMed ID: 7648289
[TBL] [Abstract][Full Text] [Related]
17. Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial.
Mark KE; Corey L; Meng TC; Magaret AS; Huang ML; Selke S; Slade HB; Tyring SK; Warren T; Sacks SL; Leone P; Bergland VA; Wald A
J Infect Dis; 2007 May; 195(9):1324-31. PubMed ID: 17397003
[TBL] [Abstract][Full Text] [Related]
18. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes.
Sperling RS; Fife KH; Warren TJ; Dix LP; Brennan CA
Sex Transm Dis; 2008 Mar; 35(3):286-90. PubMed ID: 18157071
[TBL] [Abstract][Full Text] [Related]
19. Lactoferricin but not lactoferrin inhibit herpes simplex virus type 2 infection in mice.
Shestakov A; Jenssen H; Nordström I; Eriksson K
Antiviral Res; 2012 Mar; 93(3):340-5. PubMed ID: 22269645
[TBL] [Abstract][Full Text] [Related]
20. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
Da Costa XJ; Morrison LA; Knipe DM
Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
